Skip to main content

Table 3 Estimated odds ratios for achievement of categorical outcomes with IDegLira group versus ICT during follow-up

From: Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

Categorical outcome

3 months

6 months

12 months

18 months

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

HbA1c ≤7.0% (53.0 mmol/mol)

3.52

1.36; 9.09

0.0011

1.77

0.67; 4.64

0.145

2.26

1.05; 4.88

0.0086

3.36

1.52; 7.42

0.00015

HbA1c ≤7.0% (53.0 mmol/mol) without hypoglycaemia

6.83

2.59; 18.00

< 0.0001

3.10

1.18; 8.11

0.0039

3.90

1.70; 8.93

< 0.0001

6.71

2.75; 16.37

< 0.0001

HbA1c ≤7.0% (53.0 mmol/mol) without weight gain

5.77

1.97; 16.89

< 0.0001

3.67

13.7; 9.80

0.0011

7.48

2.80; 19.94

< 0.0001

7.81

2.73; 22.31

< 0.0001

HbA1c ≤7.0% (53.0 mmol/mol) without hypoglycaemia or weight gain

10.46

2.76; 39.59

< 0.0001

5.98

1.91; 18.66

0.0001

8.55

2.86; 25.5

< 0.0001

10.47

3.27; 35.50

< 0.0001

  1. Estimated for a person with the following baseline characteristics: 62 years of age, HbA1c of 8.4% (68.3 mmol/mol), diabetes duration of 9.1 years, body weight of 91 kg, body mass index of 32.0 kg/m2 using generalized least squares regression (n = 299 people, n = 889 observations). OR [95% CI] presented for IDegLira/ICT
  2. CI confidence interval, ICT intensified conventional insulin treatment, IDegLira insulin degludec/liraglutide, OR odds ratio